scholarly journals HER2 as a Therapeutic Target in Ovarian Cancer

10.5772/29064 ◽  
2012 ◽  
Author(s):  
Lukas C. ◽  
Yulei Wang ◽  
Garret Hampto
Keyword(s):  
Ovarian Cancer ◽  
Therapeutic Target

scholarly journals 220 Functional analysis of ZFHX4 as a novel therapeutic target in ovarian cancer

2020 ◽  
Author(s):  
Y Oyama ◽  
S Shigeta ◽  
K Tsuji ◽  
H Tokunaga ◽  
M Shimada ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Functional Analysis ◽  
Therapeutic Target ◽  
Novel Therapeutic

T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer

2016 ◽  
Vol 22 (24) ◽  
pp. 6110-6117 ◽  
Author(s):  
Yuji Ikeda ◽  
Jae-Hyun Park ◽  
Takashi Miyamoto ◽  
Naofumi Takamatsu ◽  
Taigo Kato ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Protein Kinase ◽  
Prognostic Factor ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
Lak Cell

scholarly journals Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer

2013 ◽  
Vol 14 (4) ◽  
pp. 7742-7756 ◽  
Author(s):  
Carmen Pyragius ◽  
Maria Fuller ◽  
Carmela Ricciardelli ◽  
Martin Oehler
Keyword(s):  
Ovarian Cancer ◽  
Lipid Metabolism ◽  
Therapeutic Target

scholarly journals Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

2011 ◽  
Vol 17 (18) ◽  
pp. 6083-6096 ◽  
Author(s):  
Jermaine Coward ◽  
Hagen Kulbe ◽  
Probir Chakravarty ◽  
David Leader ◽  
Vessela Vassileva ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Interleukin 6 ◽  
Therapeutic Target ◽  
Human Ovarian Cancer

WASF2 Serves as a Potential Biomarker and Therapeutic Target in Ovarian Cancer: A Pan-Cancer Analysis

2021 ◽  
Author(s):  
Xiaofeng Yang ◽  
Yuzhen Ding ◽  
Lu Sun ◽  
Meiting Shi ◽  
Ping Zhang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Therapeutic Target ◽  
Potential Biomarker ◽  
Pan Cancer

scholarly journals Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Meng Zhang ◽  
Qiyu Liu ◽  
Mingxing Zhang ◽  
Cong Cao ◽  
Xiaoxia Liu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Glucose Metabolism ◽  
Therapeutic Target ◽  
Follicle Stimulating Hormone ◽  
Systemic Toxicity ◽  
Ovarian Cancer Cells ◽  
Antitumor Effects ◽  
Hexokinase 2 ◽  
Nanoparticle Complex ◽  
Stimulating Hormone

Abstract Background Most cancers favor glycolytic-based glucose metabolism. Hexokinase-2 (HK2), the first glycolytic rate-limiting enzyme, shows limited expression in normal adult tissues but is overexpressed in many tumor tissues, including ovarian cancer. HK2 has been shown to be correlated with the progression and chemoresistance of ovarian cancer and could be a therapeutic target. However, the systemic toxicity of HK2 inhibitors has limited their clinical use. Since follicle-stimulating hormone (FSH) receptor (FSHR) is overexpressed in ovarian cancer but not in nonovarian healthy tissues, we designed FSHR-mediated nanocarriers for HK2 shRNA delivery to increase tumor specificity and decrease toxicity. Results HK2 shRNA was encapsulated in a polyethylene glycol-polyethylenimine copolymer modified with the FSH β 33–53 or retro-inverso FSH β 33–53 peptide. The nanoparticle complex with FSH peptides modification effectively depleted HK2 expression and facilitated a shift towards oxidative glucose metabolism, with evidence of increased oxygen consumption rates, decreased extracellular acidification rates, and decreased extracellular lactate and glucose consumption in A2780 ovarian cancer cells and cisplatin-resistant A2780CP counterpart cells. Consequently, cell proliferation, invasion and migration were significantly inhibited, and tumor growth was suppressed even in cisplatin-resistant ovarian cancer. No obvious systemic toxicity was observed in mice. Moreover, the nanoparticle complex modified with retro-inverso FSH peptides exhibited the strongest antitumor effects and effectively improved cisplatin sensitivity by regulating cisplatin transport proteins and increasing apoptosis through the mitochondrial pathway. Conclusions These results established HK2 as an effective therapeutic target even for cisplatin-resistant ovarian cancer and suggested a promising targeted therapeutic approach.

Sign in / Sign up

Export Citation Format

Share Document